A Rare Disease Specialist Fluent in the Project Location’s Language

Summer Foote

Share this Article
Facebook
Twitter
Email
LinkedIn

In an effort to inform its Rare Diseases commercial strategy within a specific country, an F100 pharmaceutical company was looking to gain a deeper understanding of the current competitive landscape and market access scenarios for a set of pharmaceutical assets. Needing a skilled market landscape consultant who could fluently speak the country’s primary language and work on-site, the company reached out to Business Talent Group (BTG). BTG’s Talent Solutions team delivered a biopharma commercialization and launch expert who not only met the language and location requirements, but also brought deep rare disease expertise, as well as big-firm consulting experience developing pharma commercial strategies.

On-Demand Talent for Innovation, Transformation, and Growth in Life Sciences

Independent talent provide an agile source of critical skills that allow life science leaders to keep pace ...

Navigating a New Reality: Commercial Strategy and COVID-19

Commercial strategy leaders must prepare now to ensure success for potential COVID-19 treatments. Biopharma...

Other content in this Stream

The Lasting Impact of COVID-19 on U.S. Pharma Marketing

A Rare Disease Specialist Fluent in the Project Location’s Language

Previous Article

Next Article

Other content in this Stream

How can pharma marketers remain effective and relevant for key customers, patients, and healthcare providers (HCPs) in the time of COVID-19?

On-demand talent is a critical resource for life science and pharma companies as they innovate to keep pace with market changes, respond to emerging health threats, and adapt to a remote environment.

Independent talent provide an agile source of critical skills that allow life science leaders to keep pace in a fast-changing environment.

Commercial strategy leaders must prepare now to ensure success for potential COVID-19 treatments. Biopharma expert Marc Cooley shares what life science companies should keep in mind at this moment.

COVID-19 is sidelining the field reps that life science companies rely on for in-person pharmaceutical detailing. Healthcare marketing strategist Martine Taylor discusses how eDetailing can help.

Independent biopharma marketer Kimberly Crichton explains how technology is changing the way life science companies launch products and communicate with consumers and healthcare providers.

Life Science project leader Ron Niesen discusses pharma product launch best practices, from gathering data to streamlining decisions.

A global biopharmaceutical company was preparing to launch a promising new rare disease therapy in the UK and Europe. Concerned that the company’s functional leads were too busy managing existing...

Independent commercial operations expert David Davidovic talks about assessing new technologies, making fast decisions, and building commercial centers of excellence.

A major pharmaceutical company was pursuing multiple indications for a groundbreaking oncology therapy. Struggling to keep up with the work, the global marketing team concluded it would need to...

Get results-driven consultants and project managers for your marketing, sales, operations and analytics initiatives.

These days, you'd be hard-pressed to find a life science company that doesn't strive for patient centricity. But what does patient-centric marketing mean?

The lines are blurring between U.S. healthcare payers and providers. What does this payer/provider consolidation mean for pharma? Nothing less than a total shift in the way it does business. If...

A major biopharmaceutical company had developed a breakthrough medication that stood to dramatically disrupt the market for its therapeutic area. Expected to be approved by the FDA in the next...

By now, the story is familiar: new techniques in AI and data analysis are revolutionizing business decisions and driving productivity, innovation, and efficiency across the enterprise.

If you work in Life Science, you’re probably familiar with the sobering statistics on nonadherence: between 20% and 30% of medication prescriptions are never filled, and roughly 50% of chronic...

The head of strategy at a health services company had ambitious plans for growth, but needed to mitigate risk by re-examining his payer strategy. Unfortunately, his internal team was...

A medical device manufacturer had just launched a product that dramatically cut patient recovery time—as well as recovery-related expenses. Could the company accelerate sales by working with...

The VP of Business Development at an F200 health company was struggling with pricing pressures following the commoditization of a key product. The strategy leader for the product’s division wanted...

The head of global marketing at a Fortune 100 life science company faced gaps in his team’s capabilities after an enterprise-wide reorganization. As he prepared to re-launch a product within its...